文献速递免疫规划

纳米包裹维A酸作为鼻腔接种抗皮肤利什曼病的耐受性佐剂

Nanoencapsulated retinoic acid as a safe tolerogenic adjuvant for intranasal vaccination against cutaneous leishmaniasis.
PubMed 文献 · Vaccine · 2019-05-24

研究评估纳米包裹维A酸(RA-SLN)作为鼻腔接种亚马逊利什曼原虫抗原(LaAg)佐剂的安全性与效果。BALB/c小鼠接受两剂LaAg或LaAg/RA-SLN后攻击感染,RA-SLN无鼻黏膜刺激,且联合疫苗较单用抗原更有效延迟病变生长并减少寄生虫负荷。

要点

  • RA-SLN鼻腔给药未引起鼻黏膜组织学刺激或炎症。
  • LaAg/RA-SLN联合疫苗较单用LaAg更有效延迟病变生长和降低寄生虫负荷。
  • RA-SLN在黏膜处促进IL-10表达和CD4+ Foxp3+ Treg群体增加。

核心结论

  • RA-SLN是安全有效的耐受性佐剂,可改善鼻腔接种LaAg对抗利什曼病的保护效果。

研究设计与样本

  • BALB/c小鼠接受两剂鼻腔接种LaAg或LaAg/RA-SLN,随后以亚马逊利什曼原虫攻击感染。

主要发现

  • LaAg/RA-SLN延迟病变生长和减少寄生虫负荷的效果优于单用LaAg,分别降低96%和61%。
  • 攻击后两个月,两疫苗接种组均显示相似的Th1偏向原位细胞因子反应。
  • 早期感染时Th1和Th2反应均被抑制,但RA-SLN组TGF-β mRNA更高。
  • 黏膜处RA-SLN促进IL-10表达增强和CD4+ Foxp3+ Treg群体增加。

临床怎么用

  • RA-SLN可作为鼻腔疫苗的耐受性佐剂,用于诱导黏膜免疫耐受并增强保护性应答。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Mucosal, but not peripheral, vaccination with whole Leishmania amazonensis antigen (LaAg) effectively protects mice against leishmaniasis, likely through a tolerogenic mechanism. Given the crucial role of retinoic acid (RA) in CD4+ Foxp3+ regulatory T cell (Treg) differentiation and mucosal tolerance, here we evaluated the capacity of RA to improve intranasal (i.n.) vaccination with LaAg. To prevent degradation and possible mucosa irritation, RA was encapsulated in solid lipid nanoparticles (RA-SLN). Thus, BALB/c mice were given two i.n. doses of LaAg alone or in association with RA-SLN (LaAg/RA-SLN) prior to challenge with L. amazonensis. No histological sign of irritation or inflammation was produced in the nasal mucosa after RA-SLN administration. LaAg/RA-SLN vaccine was more effective in delaying lesion growth and reducing parasite burdens than LaAg alone (96% and 61% reduction, respectively). At two months after challenge, both vaccinated groups displayed similar T helper (Th) 1-skewed in situ cytokine responses, different from early infection where both Th1 and Th2 responses were suppressed, except for transforming growth factor (TGF)-β mRNA, that was higher in mice given RA-SLN. At the mucosa, RA-SLN promoted enhanced expression of interleukin (IL)-10 and CD4+ Foxp3+ Treg population. In sum, these data show that RA-SLN is an effective and safe tolerogenic adjuvant for i.n. vaccination against leishmaniasis.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Bezerra IPS, Costa-Souza BLS, Carneiro G, et al. Nanoencapsulated retinoic acid as a safe tolerogenic adjuvant for intranasal vaccination against cutaneous leishmaniasis. Vaccine. 2019. PMID: 31133469. doi:10.1016/j.vaccine.2019.05.043

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。